Clinical Trials
42 trialsRuxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
CD45BE-HSPC + CART-45 Cells
University of Pennsylvania
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
University of Virginia
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
M.D. Anderson Cancer Center
24CT015
Children's Hospital of Philadelphia
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
CAR-37 T Cells in Hematologic Malignancies
Massachusetts General Hospital
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Beijing Boren Hospital
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
Northwestern University
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Beijing Boren Hospital
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
The First Affiliated Hospital of Bengbu Medical University
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Yale University
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Columbia University
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
RID
Yale University
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Yale University
Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)
M.D. Anderson Cancer Center
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
SCRI Development Innovations, LLC
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
Nevada Cancer Institute
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Weill Medical College of Cornell University